Variable | Part 1: Logistic Regression EQ-5L-3L = 1 | Part 2: Generalized Linear Model, EQ-5L-3L < 1 | ||||
---|---|---|---|---|---|---|
Odds ratio | 95% CI | p-value | Co-efficient | 95% CI | p-value | |
South Africa | ||||||
Male (ref female) | 1.85 | 1.19, 2.87 | 0.006 | - | - | - |
Comorbidities (ref no CM) | 0.29 | 0.18, 0.46 | < 0.001 | - | - | - |
HIV treatment side effects (ref no SE) | 0.39 | 0.20, 0.75 | 0.005 | -0.08 | -0.14, -0.02 | 0.008 |
Opportunistic infection (ref no OI) | - | - | - | -0.10 | -0.15, -0.05 | < 0.001 |
Viral load > 50,000 (ref VL≤50,000) | - | - | - | -0.06 | -0.11, -0.01 | 0.029 |
100% Adherence | - | - | - | 0.07 | 0.02, 0.13 | 0.007 |
Uganda | ||||||
Male (ref female) | 1.87 | 1.24, 2.84 | 0.003 | - | - | - |
Comorbidities (ref no CM) | 0.56 | 0.35, 0.90 | 0.016 | - | - | - |
Opportunistic infection (ref no OI) | 0.41 | 0.23, 0.72 | 0.002 | - | - | - |
100% Adherence (ref < 100%) | 1.64 | 1.00, 2.70 | 0.049 | - | - | - |
CD4 | ||||||
<200 (ref) | ||||||
200–499 | - | - | - | 0.07 | 0.01, 0.13 | 0.027 |
≥ 500 |  |  |  | 0.11 | 0.04, 0.17 | 0.001 |